Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer Pfizer CEO Ian Read walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion ...

ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Pfizer pulls thousands of bottles of children’s and infants’ Advil in Canada

Eric Palmer Parents needing to treat their children during this cold season are facing another hurdle after Pfizer pulled 126 lots of children's and infants' Advil products ...

Pfizer looks to Russian partnership to produce some of its meds there, report says

Eric Palmer Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's ...

NHS watchdog takes issue with Pfizer exec’s new role on foundation trust’s board

Tracy Staton A top Pfizer executive joined the board of a National Health Service Trust in England, triggering questions about potential conflicts of interest, an NHS-focused news service ...

Big question for Pfizer: Will Enbrel’s EU biosim bring on the pain?

Carly Helfand Amgen and Pfizer's Enbrel officially has a biosimilar rival in Europe. And if the rollout goes anything like the recent EU launch of Remicade copy Remsima, the blockbuster ...

Pfizer expands consumer biz in China with Treerly supplements buy

Tracy Staton Pfizer's consumer health unit is said to be destined for sale, but that doesn't mean the business has stopped making its own buys. The drug giant snapped up ...

Pfizer looks to cut the line in CAR-T with off-the-shelf approach

Damian Garde Pfizer, breaking into the field of re-engineered T cells for cancer, believes its work with partner Cellectis could eventually top the efforts of more advanced rivals including ...

For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg

Emily Wasserman Pfizer has been contemplating a large-scale breakup for a while, with analysts expecting the company to split off its established drugs business once it integrates assets ...

Allergan’s pipeline doesn’t get enough respect, if you ask Pfizer

Damian Garde Pfizer, wending toward a record-setting $ 160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry ...

Pfizer CEO: Allergan deal is ‘a lot more about growth’ than job cuts

Carly Helfand Anyone who's examined Pfizer's job-chopping track record knows the company has a tendency to wield the ax in the wake of a megamerger. But this time? Things will ...

#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more

Carly Helfand SAN FRANCISCO–On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis ...
Page 1 of 1112345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS